Endo International PLC (ENDP) Stock Rating Lowered by Zacks Investment Research

Mae Love
November 13, 2017

According to Zacks, "Endo withdrew opioid pain medication Opana ER (oxymorphone hydrochloride extended release) from the market following FDA's request in June". The generic business is under significant pressure due to intensifying consortium pricing pressures, and additional competitive entrants and product discontinuations as well as discrete factors, including destocking and shifts in purchase timing due to market conditions. The firm has "Hold" rating by Stifel Nicolaus given on Friday, September 15. The forecast of 2 surveyed investment analysts covering the stock advises investors to Buy stake in the company. On Friday, April 29 the stock rating was maintained by Citigroup with "Buy".

Let's have a look at some of the important valuation ratios of the Endo International plc (ENDP). Finally, Cantor Fitzgerald set a $9.00 price objective on Endo International PLC and gave the company a "hold" rating in a report on Tuesday, August 8th. Four analysts have rated the stock with a sell rating, fifteen have issued a hold rating and five have issued a buy rating to the company's stock. Closing price generally refers to the last price at which a stock trades during a regular trading session. Endo International plc (NASDAQ:ENDP)'s short interest is 19.65 million shares, or 9.86% of the float. Endo International PLC has a 52-week low of $12.56 and a 52-week high of $63.71. The new target price indicates a possible upside of 0.48% based on the company's last stock close price.

Institutional investors now hold around $1.26 billion or 88.8% in ENDP stock.

According to analysts Endo Int'l Plc (NASDAQ:ENDP)'s minimum EPS for the current quarter is at $0.61 and can go high up to $0.78. Comparatively, Endo International plc posted earnings of $1.09 per share in the same quarter past year. The firm had revenue of $786.90 million for the quarter, compared to analysts' expectations of $794.93 million.

Sierra Nevada Dream Chaser Conducts Critical Flight Test
This weekend's free-flight test was the second one that Sierra Nevada has done with Dream Chaser. In previous tests in 2017, a helicopter carried the Dream Chaser aloft but did not release it.

Rand Paul to return to Senate after injuries
Neither Paul's communication staff nor Matt Baker, the attorney for Boucher, have indicated what led to the apparent attack. Porter said Paul was wearing ear protection, so he did not hear the attack coming.

Sensex, Nifty log first fall in 3 days; Adani Ports, CIL drag
TCS, Mahindra & Mahindra and Sun Pharma were the major gainers while Adani Ports, ONGC and Aurobindo Pharma lost the most. The decline - close to 1% for the Sensex and the Nifty - was all but pervasive across sectors.

While considering growth estimates of the company, it has next quarter growth estimates of -43.9% whereas during current quarter it has -60.5% estimations over growth, comparing to the estimations of -24.9% during current year and -15.2% for next year. Analysts predict that Endo International PLC will post $4.60 EPS for the current fiscal year. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and worldwide copyright and trademark law. Susquehanna raised shares of Endo International PLC from a "neutral" rating to a "positive" rating and set a $20.00 price objective on the stock in a research note on Thursday, November 10th. The stock is a Buy among 6 brokerage firms polled by Factset Research. The stock closing price is now trading downward to its 50 day moving average with change of -12.79%, escalated to its 20 day moving average with figure of 1.27% and behind its 200 day moving average with value -33.69%. Over the last ninety days, insiders have bought 16,000 shares of company stock valued at $125,460. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insider ownership increased by a total of 13348 shares, which suggests that ENDP's key executives are feeling more optimistic about the outlook for the stock.

Several hedge funds have recently added to or reduced their stakes in ENDP. Heartland Advisors Inc. acquired a new stake in shares of Endo International PLC during the second quarter worth approximately $15,627,000.

Relative strength index (RSI-14) for Endo International plc (ENDP) is at 48.76. Amer Incorporated has 0.86% invested in Endo International plc - Ordinary Shares (NASDAQ:ENDP). Point View Wealth Management Inc. lifted its position in shares of Endo International PLC by 16.6% during the second quarter. The shares were sold at an average price of $17.38, for a total transaction of $243,320.00.

Other reports by

Discuss This Article